Protocol Search

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Study Title Status Phase Disease Category Disease Site
NRG-HN007An Open Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActiveIIIHead and Neck [HN]Head and Neck
EA8185ECOG-ACRIN/NRG Joint Study:A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE StudyOpen to AccrualIIGenitourinary [GU]Bladder
NRG-LU007RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR TrialOpen to AccrualII/IIILung [LU]Small Cell
GOG-0210A Molecular Staging Study of Endometrial CarcinomaTerminatedIGynecologic [GY]Uterine Corpus
NRG-BN007A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide In Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated GlioblastomaActiveII/IIIBrain [BN]Malignant Glioma
NRG-CC008A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]Open to AccrualOtherGynecologic [GY]Ovarian
NRG-HN006Randomized Phase II/III Trial Of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection For Early-Stage Oral Cavity CancerActiveII/IIIHead and Neck [HN]Other
NRG-GI007Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for SurgeryOpen to AccrualIGastrointestinal [GI]Esophageal
S1914SWOG/NRG Joint Study: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLCOpen to AccrualIIILung [LU]Other
S1806SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer Open to AccrualIIIGenitourinary [GU]Bladder
NRG-GU008Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical ProstatectomyOpen to AccrualIIIGenitourinary [GU]Prostate
NRG-GY020A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed, High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial CancerOpen to AccrualIIIGynecologic [GY]Uterine Corpus
NRG-LU006Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)Open to AccrualIIILung [LU]Other
NRG-GI005Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA
Colon Cancer (COBRA)
Open to AccrualII/IIIGastrointestinal [GI]Colorectal
NRG-GY021A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerOpen to AccrualIIGynecologic [GY]Ovarian
NRG-GY022Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using CarboplatinOpen to AccrualIIGynecologic [GY]Other
NRG-GY019A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumOpen to AccrualIIIGynecologic [GY]Ovarian
GOG-0274 RTOG 1174A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIALClosed to AccrualIIIGynecologic [GY]Cervix
NRG-GY018A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCERTemporarily Closed to AccrualIIIGynecologic [GY]Uterine Corpus
NRG-GY014A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial AdenocarcinomaTemporarily Closed to AccrualIIGynecologic [GY]Ovarian
NRG-GU006A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate CancerClosed to AccrualIIGenitourinary [GU]Prostate
GOG-0237Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)Closed to AccrualIGynecologic [GY]Cervix
GOG-0238A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine CorpusOpen to AccrualIIGynecologic [GY]Uterine Corpus
NRG-GY012A Randomized, Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial CancerTemporarily Closed to AccrualIIGynecologic [GY]Uterine Corpus
NRG-GU007Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)Temporarily Closed to AccrualI/IIGenitourinary [GU]Prostate
RTOG-1112Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular CarcinomaOpen to AccrualIIIGastrointestinal [GI]Liver
NRG-HN005A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal CancerOpen to AccrualII/IIIHead and Neck [HN]Head and Neck
NRG-LU003A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol  Open to AccrualIILung [LU]Other
NRG-CC004Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire in Women With Breast or Gynecologic CancerClosed to AccrualIISymptom Management [CC]Other
NRG-DT001A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)Open to AccrualIOther [DT]Sarcoma
RTOG-0924Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized TrialClosed to AccrualIIIGenitourinary [GU]Prostate
NRG-LU005Limited Stage Small Cell Lung Cancer (LS-SCLC):  A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus AtezolizumabOpen to AccrualII/IIILung [LU]Small Cell
NRG-LU002Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC):  A Randomized Phase II/III TrialOpen to AccrualII/IIILung [LU]Other
NRG-GY007A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed to AccrualI/IIGynecologic [GY]Ovarian
NRG-GU003A Randomized Phase III Trial Of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)Closed to AccrualIIIGenitourinary [GU]Prostate
NRG-BR005A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without SurgeryTemporarily Closed to AccrualIIBreast [BR]Breast
NRG-CC003A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung CancerActiveII/IIISymptom Management [CC]Other
GOG-9923A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab(NSC #704865, IND #7921)and CTEP-Supplied Agent ABT-888(NSC #737664,IND# 77840)in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary PeritCancerTerminatedIGynecologic [GY]Ovarian
NSABP B-55 BIG 6-13OlympiA: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyClosed to AccrualIIIBreast [BR]Breast
GOG-0277A phase III randomized trial of gemcitabine (nsc# 613327) plus docetaxel (nsc#  628503) followed by doxorubicin (nsc# 123127) versus observation for uterus-limited, high-grade uterine leiomyosarcomaTerminatedIIIGynecologic [GY]Uterine Corpus
GOG-0260A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072) (NCT# 00888615).TerminatedIIGynecologic [GY]Ovarian
GOG-0186KA Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) versus weekly paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedIIGynecologic [GY]Ovarian
RTOG-0534A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical ProstatectomyClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-1119Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROGClosed to AccrualIIBreast [BR]Breast
NSABP B-31A Randomized Trial Comparing The Safety And Efficacy Of Adriamycin And Cyclophosphamide Followed By Taxol (AC?T) To That Of Adriamycin And Cyclophosphamide Followed By Taxol Plus Herceptin (AC?T + H) In Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2TerminatedIIIBreast [BR]Breast
NRG-GY016A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the OvaryTemporarily Closed to AccrualIIGynecologic [GY]Ovarian
GOG-9926A Phase I Evaluation of Extended Field Radiation Therapy with Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinoma Metastatic to Para-Aortic Lymph NodesTerminatedIGynecologic [GY]Cervix
NRG-GY001A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or PeritoneumTerminatedIIGynecologic [GY]Ovarian
NRG-LU004Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)Open to AccrualILung [LU]Other
RTOG-0815A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
NRG-CC007CDIncreasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation TherapyOpen to AccrualIISymptom Management [CC]Other
NRG-HN004Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to CisplatinOpen to AccrualII/IIIHead and Neck [HN]Head and Neck
COG-NRG ARST1321Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS):  A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754; IND#118613)Closed to AccrualII/IIIOther [DT]Sarcoma
NRG-BR004A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast CancerOpen to AccrualIIIBreast [BR]Breast
GOG-0213A Phase III Randomized Controlled Clinical Trial Of Carboplatin and Paclitaxel or  Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrenovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) Closed to AccrualIIIGynecologic [GY]Ovarian
NRG-GI006Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal CancerOpen to AccrualIIIGastrointestinal [GI]Esophageal
RTOG-0926A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-StagingClosed to AccrualIIGenitourinary [GU]Bladder
NSABP B-39 RTOG 0413A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast CancerTerminatedIIIBreast [BR]Breast
NSABP B-40A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the RegimensTerminatedIIIBreast [BR]Breast
NRG-GY006A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal CancerOpen to AccrualIIGynecologic [GY]Cervix
NRG-GY005A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS).Open to AccrualII/IIIGynecologic [GY]Ovarian
NRG-GY004A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed to AccrualIIIGynecologic [GY]Ovarian
GOG-0239A Phase II Trial of AZD6244 (NSC #748727, IND #77782) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or PeritoneumClosed to AccrualIIGynecologic [GY]Ovarian
NRG-BN002Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed GlioblastomaClosed to AccrualIBrain [BN]Malignant Glioma
NRG-GU005Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate CancerOpen to AccrualIIIGenitourinary [GU]Prostate
NRG-LU001Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLCClosed to AccrualIILung [LU]Other
RTOG-1106RTOG 1106/ACRIN 6697, Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Closed to AccrualIILung [LU]Other
NRG-HN001Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)Open to AccrualII/IIIHead and Neck [HN]Head and Neck
GOG-0278Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (</= 2 cm) Cervical CancerOpen to AccrualI/IIGynecologic [GY]Cervix
RTOG-1122Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or GliosarcomaClosed to AccrualIIBrain [BN]Other
NRG-GY017Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical CancerTemporarily Closed to AccrualIGynecologic [GY]Cervix
RTOG-1308Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLCOpen to AccrualIIILung [LU]Other
NRG-GI003A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular CarcinomaOpen to AccrualIIIGastrointestinal [GI]Liver
NRG-BN003Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II MeningiomaOpen to AccrualIIIBrain [BN]Benign Brain Tumors
NRG-BN005A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas.Open to AccrualIIBrain [BN]Lower Grade Glioma
NRG-HN003A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)Closed to AccrualIHead and Neck [HN]Head and Neck
RTOG-0233A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and GemcitabiTerminatedIIGenitourinary [GU]Bladder
NRG-GY003A Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerClosed to AccrualIIGynecologic [GY]Ovarian
NRG-GI002A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal CancerTemporarily Closed to AccrualIIGastrointestinal [GI]Anal Canal
AGCT1531A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsOpen to AccrualIIIGynecologic [GY]Other
NRG-GY008A Phase II Evaluation of Copanlisib BAY 80-6946 IND #130822, A Selective Inhibitor of PI3KCA, in patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot MutationsTerminatedIIGynecologic [GY]Uterine Corpus
RTOG-0627Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma MultiformeTerminatedIIBrain [BN]Other
NRG-GY002A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical CancerTerminatedIIGynecologic [GY]Cervix
NRG-BR002A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast CancerTemporarily Closed to AccrualII/IIIBreast [BR]Breast
RTOG-1114Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System LymphomaClosed to AccrualIIBrain [BN]Other
GOG-0225Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?Closed to AccrualIIIGynecologic [GY]Ovarian
NRG-GY009A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian CancerActiveII/IIIGynecologic [GY]Ovarian
NSABP BP-59Bone Marrow Analysis in Early-Stage Breast CancerTerminatedIIIBreast [BR]Breast
NSABP B-37 IBCSG 27-02A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast CancerTerminatedIIIBreast [BR]Breast
RTOG-0522A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab C225 [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck CarcinomasClosed to AccrualIIIHead and Neck [HN]Head and Neck
RTOG-9601A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy for pT3N0 Carcinoma of the ProstateClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0232A Phase III Study Comparing Combined External Beam Radiation And Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic CarcinomaClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0828Pilot Project to Reduce Missing RTOG Quality of Life Data Via Electronic Web-Based Form Collection: A Companion Study for RTOG 0415 (A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients wiClosed to AccrualIIIGenitourinary [GU]Prostate
GOG-0186HA Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin NSC # 729968, BB-IND #13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedIIGynecologic [GY]Ovarian
RTOG-1115Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0834Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup TrialClosed to AccrualIIIBrain [BN]Benign Brain Tumors
NRG-GI001Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic CholangiocarcinomaTerminatedIIIGastrointestinal [GI]Liver
RTOG-9110NCCTG 86-72-51: A Phase III Evaluation of Postoperative Radiation in Low Grade Intracranial Astrocytomas and OligodendrogliomasClosed to AccrualIIIBrain [BN]Other
RTOG-0621Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II TrialTerminatedIIGenitourinary [GU]Other
RTOG-9408A Phase III Trial of the Study of Endocrine Therapy used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the ProstateTerminatedIIIGenitourinary [GU]Prostate
RTOG-0630A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the ExtremityTerminatedIIOther [DT]Sarcoma
RTOG-1203A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP StudyClosed to AccrualIIIGynecologic [GY]Other
RTOG-0129A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck CarcinomasClosed to AccrualIIIHead and Neck [HN]Head and Neck
RTOG-1306A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)TerminatedIILung [LU]Other
RTOG-0848A Phase IIR and a Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas AdenocarcinomaClosed to AccrualII/IIIGastrointestinal [GI]Pancreas
RTOG-9402Phase III Intergroup Randomized Comparison of Radiation Alone Vs Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic OligodendrogliomasTerminatedIIIBrain [BN]Other
RTOG-0915A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung CancerTerminatedIILung [LU]Small Cell
RTOG-0618A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung CancerTerminatedIILung [LU]Small Cell
RTOG-0615A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal CancerTerminatedIIHead and Neck [HN]Head and Neck
RTOG-0131A Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic OligoastrocytomasTerminatedIIBrain [BN]CNS Metastatic Disease
RTOG-9813A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)TerminatedI/IIIBrain [BN]Other
RTOG-9802A Phase II Study of Observation in Favorable Low-Grade Glioma and Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade GliomaTerminatedII/IIIBrain [BN]Other
RTOG-0938A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer-RTOG CCOP StudyClosed to AccrualIIGenitourinary [GU]Prostate
RTOG-0813Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable PatientsClosed to AccrualI/IILung [LU]Other
RTOG-0912A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for The Treatment of Anaplastic Thyroid CancerClosed to AccrualIIHead and Neck [HN]Head and Neck
RTOG-0415A Phase III Randomized Study of Hypofractionated 3DCRT/IMRT versus Conventionally Fractionated 3DCRT/IMRT in Patients Treated for Favorable-Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0521A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0524A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive BladderClosed to AccrualI/IIGenitourinary [GU]Bladder
RTOG-9910A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0837Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed GlioblastomaClosed to AccrualIIBrain [BN]Other
RTOG-0631Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine MetastasisTerminatedII/IIISymptom Management [CC]Other
RTOG-0617A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung CancerClosed to AccrualIIILung [LU]Small Cell
RTOG-0537A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced XerostomiaTerminatedII/IIIHead and Neck [HN]Head and Neck
RTOG-1016Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx CancerClosed to AccrualIIIHead and Neck [HN]Head and Neck
RTOG-0126A Phase III Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3DCRT/IMRT in Patients Treated for Localized Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0526A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam RadiotherapyClosed to AccrualIIGenitourinary [GU]Other
RTOG-0712A Phase II Randomized Study for Patients with Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery and Concomitant Chemoradiation by Either BID Irradiation plus 5-Fluorouracil and Cisplatin or QD Irradiation plus Gemcitabine Followed by Selective Bladder Preservation and Gemcitabine/Cisplatin Adjuvant ChemotherapyClosed to AccrualIIGenitourinary [GU]Bladder
RTOG-0424A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade GliomasClosed to AccrualIIBrain [BN]Lower Grade Glioma
RTOG-0539Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk MeningiomasClosed to AccrualIIBrain [BN]Other
RTOG-0913Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed GlioblastomaClosed to AccrualI/IIBrain [BN]Other
RTOG-1014A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBRI) for Local Recurrence of Breast CarcinomaClosed to AccrualIIBreast [BR]Breast
RTOG-1205Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent GlioblastomaClosed to AccrualIIBrain [BN]Other
RTOG-0436A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without SurgeryClosed to AccrualIIIGastrointestinal [GI]Esophageal
RTOG-1010A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal AdenocarcinomaClosed to AccrualIIIGastrointestinal [GI]Esophageal
RTOG-9804Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Ductal Carcinoma In Situ (DCIS) of the Female BreastClosed to AccrualIIIBreast [BR]Breast
RTOG-1005A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer Closed to AccrualIIIBreast [BR]Breast
GOG-0263Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphdenectomy.Open to AccrualIIIGynecologic [GY]Cervix
NSABP B-47A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast CancerClosed to AccrualIIIBreast [BR]Breast
NRG-GI004Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal CancerTemporarily Closed to AccrualIIIGastrointestinal [GI]Colorectal
GOG-0281A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerClosed to AccrualII/IIIGynecologic [GY]Ovarian
GOG-9928A Phase I study of the safety of intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer) administered in combination with pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer patients. The purpose of this studtermine the safety of EGEN-001 IP plus PLD treatment in platinum-recurrent ovarian cancer patients.TerminatedIGynecologic [GY]Ovarian
GOG-9924A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240)in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedIGynecologic [GY]Ovarian
GOG-0280A Phase II Eval of the Poly(ADP-Ribose)Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888)(NSC #737644) in the tx of Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Ca in Patients who carry a germline BRCA 1 or 2 Mutation  TerminatedIIGynecologic [GY]Ovarian
RTOG-0920A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck CancerClosed to AccrualIIIHead and Neck [HN]Head and Neck
NRG-BR001A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple MetastasesClosed to AccrualIBreast [BR]Breast
NRG-CC001A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain MetastasesTerminatedIIISymptom Management [CC]Other
NSABP NCIC CTG MA.32.FBiobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast CancerClosed to AccrualIIIBreast [BR]Breast
NSABP B-52A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen DeprivationClosed to AccrualIIIBreast [BR]Breast
NSABP B-51 RTOG 1304A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyOpen to AccrualIIIBreast [BR]Breast
NSABP B-49A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerClosed to AccrualIIIBreast [BR]Breast
NSABP B-43A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by LumpectomyClosed to AccrualIIIBreast [BR]Breast
NSABP B-42A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast CancerClosed to AccrualIIIBreast [BR]Breast
NRG-BR003A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast CancerOpen to AccrualIIIBreast [BR]Breast
NRG-GY011A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine CorpusClosed to AccrualIGynecologic [GY]Uterine Corpus
NRG-HN002A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal CancerClosed to AccrualIIHead and Neck [HN]Head and Neck
GOG-0286BA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial CancerClosed to AccrualII/IIIGynecologic [GY]Uterine Corpus
RTOG-1008A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland TumorsOpen to AccrualII/IIIHead and Neck [HN]Head and Neck
RTOG-0839Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung CancerCompleteIILung [LU]Other
RTOG-0724Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical HysterectomyOpen to AccrualIIIGynecologic [GY]Ovarian
GOG-0229OA randomized phase II study with a phase I lead-in to assess the antitumor efficacy of the MEK inhibitor Trametinib alone or in combination with GSK2141795, an AKT inhibitor in patients with recurrent or persistent endometrial cancer.TerminatedIIGynecologic [GY]Uterine Corpus
RTOG-1216Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and NeckOpen to AccrualII/IIIHead and Neck [HN]Head and Neck
GOG-0209A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial CancerClosed to AccrualIIIGynecologic [GY]Uterine Corpus
GOG-0275A phase III randomized trial of pulse actinomycin-d versus multi-day methotrexate for the treatment of low-risk gestational trophoblastic neoplasiaTerminatedIIIGynecologic [GY]Other
GOG-0273Chemotherapy toxicity in elderly women with ovarian, primary peritoneal or fallopian tube cancerClosed to AccrualIIIGynecologic [GY]Ovarian
GOG-0261A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or OvaryClosed to AccrualIIIGynecologic [GY]Uterine Corpus
GOG-0258A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. Carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinomaClosed to AccrualIIIGynecologic [GY]Uterine Corpus
GOG-0252A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): BevacizumabClosed to AccrualIIIGynecologic [GY]Ovarian
GOG-0249A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high risk, early stage endometrial carcinomaTerminatedIIIGynecologic [GY]Uterine Corpus
GOG-0241A GCIG intergroup multicenter phase III trial of open label carboplatin and paclitaxel +/- NCI-supplied agent: bevacizumab (nsc #704865, ind #113912) compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous epithelial ovarian or fallopian tube cancer (MEOC)TerminatedIIIGynecologic [GY]Ovarian
GOG-0218A phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (nsc #704865, ind #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women newly diagnosed, previously untreated, stage III or IV, epithelial ovarian, primary peritoneal or fallopian tube cancer nci-supplied agent(s): bevacizumab/ placeboTerminatedIIIGynecologic [GY]Ovarian
GOG-0283A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, Endometrial, or Endometriosis-Associated Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expsion.Closed to AccrualIIGynecologic [GY]Ovarian
GOG-0270Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V)II: An Observational StudyClosed to AccrualIIGynecologic [GY]Other
GOG-0265A Phase II Evaluation of ADXS11-001 (IND #13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix (NCT# 01266460).TerminatedIIGynecologic [GY]Cervix
GOG-0244The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors and Impact in Newly Diagnosed PatientsTerminatedIGynecologic [GY]Other
GOG-0212A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or ct-2103 (ind# 70177) versus no treatment until documented relapse in women with advanced ovarian, primary peritoneal or fallopian tube cancer who achieve a complete clinical response to primary platinum/taxane chemotherapyClosed to AccrualIIIGynecologic [GY]Ovarian
SWOG-S1207 NSABP B-53Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer: e3 Breast Cancer Study - Evaluating Everolimus with Endocrine TherapyOpen to AccrualIIIBreast [BR]Breast
SWOG-S1418 NRG-BR006A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant ChemotherapyOpen to AccrualIIIBreast [BR]Breast
GOG-0264A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary.Closed to AccrualIIGynecologic [GY]Ovarian
NRG-GU001Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder CancerTerminatedIIGenitourinary [GU]Bladder
GOG-9929A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients with Locally Advanced Cervical Cancer Stages IB2/IIA with Positive Para-aortic Lymph Nodes and Only Stage IIB/IIIB/IVA with Positive Lymph NodesTerminatedIGynecologic [GY]Cervix
NRG-BN001Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed GlioblastomaOpen to AccrualIIBrain [BN]Malignant Glioma
NRG-CC002Pre-Operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic CancersTerminatedIGynecologic [GY]Other
NRG-GU002NRG-GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant DocetaxelOpen to AccrualII/IIIGenitourinary [GU]Prostate
GOG-0279A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the VulvaClosedIIGynecologic [GY]Other
GOG-0170RA Phase II Evaluation of Dalantercept (NSC #757172, IND #116598), A Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primry Peritoneal CarcinomaTerminatedIIGynecologic [GY]Ovarian
GOG-0262A Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #113912) in the Treatment of Primary Stage III or IV Epthelial Ovarian, Peritoneal or Fallopian Tube CancerClosed to AccrualIIIGynecologic [GY]Ovarian